期刊文献+

中国人CYP2C9基因多态性对华法林维持剂量影响的Meta分析 被引量:6

Effect of CYP2C9 genetic polymorphism on maintenance warfarin dosage in Chinese: A Metaanalysis
下载PDF
导出
摘要 目的分析中国人CYP2C9基因多态性对华法林维持剂量的影响。方法检索2000-2011年相关中英文数据库,用stata10.0软件进行Meta分析。结果共纳入16项研究(共2 361人)。中国人CYP2C9各等位基因型频率为野生型CYP2C9*193.99%,突异型CYP2C9*2 0.06%,CYP2C9*3 5.95%。与野生型*1/*1型相比,*1/*3和*3/*3型华法林维持剂量分别减少26.8%(95%CI 18.8%,34.8%)和26.3%(95%CI 12.6%,39.9%),亚组分析、剪补法校正及敏感性分析表明该结果稳定、可信。结论中国人CYP2C9基因多态性频率与其他种族不同,对华法林维持剂量具有重要影响。 Objective To analyze the effect of CYP2C9 genetic polymorphism on maintenance warfarin dosage in Chinese.Methods A meta-analysis of studies about the effect of CYP2C9 genetic polymorphism on maintenance warfarin dosage in Chinese covered in related databases from 2000 to 2011 was performed using Stata10.0 software.Results Sixteen studies involving 2 361 patients were included in the meta-analysis.The wild-type CYP2C9*1,mutant CYP2C9*2 and CYP2C9*3 accounted for 93.99%,0.06%,and 5.95%,respectively,of CYP2C9 alleles in Chinese.The maintenance warfarin dosage for genotypes CYP2C9*1/*3 and CYP2C9*3/*3 was 26.8%(95%CI 18.8%,34.8%) and 26.3%(95%CI 12.6%,39.9%) lower than that of wild-type CYP2C9 *1/*1.Subgroup analysis and sensitivity analysis demonstrated that the results of meta-analysis were stable and reliable.Conclusion CYP2C9 genetic polymorphism in Chinese populations is different from that in other races and exerts an important effect on maintenance warfarin dosage.
出处 《军医进修学院学报》 CAS 2012年第3期228-230,240,共4页 Academic Journal of Pla Postgraduate Medical School
关键词 华法林 CYP2C9 基因多态性 META分析 中国人 warfarin CYP2C9 genetic polymorphism Meta-analysis Chinese
  • 相关文献

参考文献19

  • 1Wadelius M,Pirmohamed M.Pharmacogenetics of warfarin:currentstatus and future challenges[J].Pharmacogenomics J,2007,7(2):99-111. 被引量:1
  • 2Lindh JD,Holm L,Andersson ML,et al.Influence of CYP2C9genotype on warfarin dose requirements--a systematic review andmeta-analysis[J].Eur J Clin Pharmacol,2009,65(4):365-375. 被引量:1
  • 3Veenstra DL,You JH,Rieder MJ,et al.Association of vitamin K epoxide reductase complex 1(VKORC1)variants with warfarin dose in a Hong Kong Chinese patient population[J].Pharmacogenet Genomics,2005,15(10):687-691. 被引量:1
  • 4Miao L,Yang J,Huang C,et al.Contribution of age,body weight,and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin:proposal for a new dosing regimen in Chinese patients[J].Eur J Clin Pharmacol,2007,63(12):1135-1141. 被引量:1
  • 5霍梅,刘春,杨超,李体远,龚亮.华法林抗凝治疗维持剂量与CYP2C9基因突变的关系[J].中国慢性病预防与控制,2008,16(1):35-37. 被引量:4
  • 6张亚楠..CYP4502C9和VKORC1的基因多态性及其他因素与华法林剂量的相关性研究[D].河北医科大学,2008:
  • 7郑策,梅丹,管珩.CYP2C9遗传多态性与华法林剂量和抗凝效果的关系研究[J].中国药学杂志,2008,43(11):862-865. 被引量:9
  • 8黄盛文..VKORC1和CYP2C9基因型对中国人华法林个体化用药剂量影响的前瞻性研究[D].南方医科大学,2008:
  • 9程琼..基因多态性对老年房颤患者华法林代谢和药效的影响[D].福建医科大学,2008:
  • 10章伟平,陈慧,骆杰伟,吴小盈.CYP2C9 1061 A/C与VKORC1-1639 G/A基因多态性对华法林应用剂量的影响[J].医学分子生物学杂志,2007,4(5):396-400. 被引量:8

二级参考文献102

  • 1涂向东,江清华,兰风华.三种简易提取全血基因组DNA方法的比较[J].中国实验诊断学,2006,10(3):264-266. 被引量:29
  • 2ZHAO F,LOKE C,RANKIN S C,et al.Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose[J].Clin Pharmacol Ther,2004,76(3):210-219. 被引量:1
  • 3PALKIMAS M P,SKINNER H M,GANDHI P J,et al.Polymorphism induced sensi-tivity to warfarin:a review of the literature[J].J Tromb Thrombolysis,2003,15 (3):205-211. 被引量:1
  • 4SULLIVAN-KLOSE T H,GHANAYEM B I,BELL D A,et al.The role of the CYP2Cg-Leu359 allelic variant in the tolbutamide Polymorphism[J].Pharmacogenetics,1996,6(4):341-349. 被引量:1
  • 5YASAR U,ELIASSON E,DAHL M L,et al.Validation of methods for CYP2C9 genotyping:frequencies of mutant alleles in a Swedish population[J].Biochem Biophys Res Commum,1999,254:628 -631. 被引量:1
  • 6HIGASHI M K,VEENSTRA D L,KONDO L M,et al.Association between CYP2C9 genetievariant and anticoagulation-related outcomes during warfarin therapy[J].JAMA,2002,287 (13):1690-1698. 被引量:1
  • 7WITTKOWSKY A K,DEVINE E B.Frequency and causes of overantieoagula-tion and underanticoagulation in patients treated with warfarin[J].Pharmacotherapy,2004,24(10):1311-1316. 被引量:1
  • 8SCORDO M G,PENGO V,SPINA E,et al.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J].Clin Pharmacol Ther,2002,72(6):702-710. 被引量:1
  • 9GAGE B F,EBY C,MILLIGAN P E,et al.Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin[J].Thromb Haemost,2004,91 (1):87-94. 被引量:1
  • 10Aithal G P, Day C P, Kesteven P J, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [ J ]. Lancet, 1999, 353 (9154) : 717 -719. 被引量:1

共引文献91

同被引文献91

  • 1唐和年,杜宇奎,张总刚,郭永忠,阿不拉江,郭盛,马中原,阿依别克,刘军,李明.新疆汉族和维吾尔族机械瓣膜置换术后低强度抗凝条件下华法林维持剂量与CYP2C9和VKORC1基因多态性的相关性研究[J].中国医药,2007,2(4):216-220. 被引量:7
  • 2张海英,张斌,李玉珍.华法林的相互作用及其安全应用[J].药物不良反应杂志,2007,9(2):112-116. 被引量:65
  • 3Feldstein AC, Smith DH, Perrin N, et al. Reducing warfarin medication interactions: an interrupted time series evaluation[J]. Arch Intern Med,2006,166(9):1009-1015. 被引量:1
  • 4Weinshilboum R. Inheritance and drug response[J]. N Engl J Med, 2003,348(6):529-537. 被引量:1
  • 5Hering D, Piper C, Horstkotte D. Drug insight: an overview of current anticoagulation therapy after heart valve replacement[J]. Nat Clin Pract Cardiovasc Med, 2005,2(8):415-422. 被引量:1
  • 6Hirsh J, Dalen J, Anderson DR,et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range[J]. Chest, 2001,119(1 Suppl):S8-21. 被引量:1
  • 7Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy[J]. Pharmacogenetics, 1995,5(6):389-392. 被引量:1
  • 8Hauta-Aho M, Tirkkonen T, Vahlberg T,et al. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients[J]. Ann Med, 2009,41(8):619-628. 被引量:1
  • 9Spina E, Santoro V, D′Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update[J]. Clin Ther, 2008,30(7):1206-1227. 被引量:1
  • 10Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling[J]. Clin Pharmacol Ther, 2007,81(2):298-304. 被引量:1

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部